Z Ping Lin
Overview
Explore the profile of Z Ping Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whitlock B, Ma Y, Conseil G, OBrien A, Banerjee M, Swanlund D, et al.
Drug Metab Dispos
. 2024 Sep;
52(12):1417-1428.
PMID: 39313329
Millions of people globally are exposed to the proven human carcinogen arsenic at unacceptable levels in drinking water. In contrast, arsenic is a poor rodent carcinogen, requiring >100-fold higher doses...
2.
Ma M, Lavi E, Altwerger G, Lin Z, Ratner E
PLoS One
. 2024 Jul;
19(7):e0305273.
PMID: 38976671
Epithelial ovarian cancer (EOC) has a low overall survival rate, largely due to frequent recurrence and acquiring resistance to platinum-based chemotherapy. EOC with homologous recombination (HR) deficiency has increased sensitivity...
3.
Lavi E, Lin Z, Ratner E
iScience
. 2023 Oct;
26(10):107934.
PMID: 37810216
Ovarian cancer is the deadliest gynecologic malignancy in women, with a 46% five-year overall survival rate. The objective of the study was to investigate the effects of non-homologous end-joining (NHEJ)...
4.
Roberts C, Rojas-Alexandre M, Hanna R, Lin Z, Ratner E
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568736
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, largely due to metastasis and drug resistant recurrences. Fifteen percent of ovarian tumors carry mutations in BRCA1 or BRCA2, rendering...
5.
Al Zouabi N, Roberts C, Lin Z, Ratner E
Methods Mol Biol
. 2021 May;
2255:43-53.
PMID: 34033093
Phenotypic analysis of the effects of a gene of interest may be limited because stable expression of some genes leads to adverse consequences in cell survival, such as disturbance of...
6.
Lin Z, Al Zouabi N, Xu M, Bowen N, Wu T, Lavi E, et al.
Sci Rep
. 2021 Apr;
11(1):8042.
PMID: 33850183
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration...
7.
Lin Z, Zhu Y, Lo Y, Moscarelli J, Xiong A, Korayem Y, et al.
PLoS One
. 2018 Nov;
13(11):e0207399.
PMID: 30444904
PARP inhibitors target BRCA mutations and defective homologous recombination repair (HRR) for the treatment of epithelial ovarian cancer (EOC). However, the treatment of HRR-proficient EOC with PARP inhibitors remains challenging....
8.
Lin Z, Zhu Y, Ratner E
Front Oncol
. 2018 Aug;
8:303.
PMID: 30135856
Ovarian, uterine/endometrial, and cervical cancers are major gynecologic malignancies estimated to cause nearly 30,000 deaths in 2018 in US. Defective cell cycle regulation is the hallmark of cancers underpinning the...
9.
Whicker M, Lin Z, Hanna R, Sartorelli A, Ratner E
BMC Cancer
. 2016 Jul;
16:550.
PMID: 27465688
Background: Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation of the AKT pathway promotes platinum resistance while inhibition of AKT sensitizes chemoresistant cells....
10.
Ishiguro K, Zhu Y, Lin Z, Penketh P, Shyam K, Zhu R, et al.
J Transl Sci
. 2016 Apr;
2(2):117-124.
PMID: 27076919
Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines...